Compared to free drugs, the codelivery of JQ1 and the cyclin-dependent kinase 7 inhibitor THZ1 significantly enhanced tumour-inhibition effects in a gemcitabine-resistant pancreatic ductal adenocarcinoma patient-derived xenograft model [33]. This evidence concerns the gene CDK7 and pancreatic ductal adenocarcinoma.